Quantcast

Latest Neuroendocrine tumor Stories

2011-08-02 00:00:31

A targeted and personalized medicine approach to lung cancer. Somerville, MA (PRWEB) August 01, 2011 Andarix Pharmaceuticals, a clinical stage company, announces the appointment of leading clinical oncology experts to its clinical advisory board.

2011-06-30 13:46:02

A new treatment option may soon be available for children with neuroblastoma.

2011-05-20 17:14:00

MANHATTAN BEACH, Calif., May 20, 2011 /PRNewswire/ -- The Pfizer drug Sutent® (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA).

2011-05-20 15:34:00

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S.

2011-05-06 08:55:00

MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.

2011-05-06 08:54:00

SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- On Thursday, the U.S.

2011-05-05 17:50:00

EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4).

2011-04-12 13:59:00

EAST HANOVER, N.J., April 12, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. The recommendation was provided after presentation of data from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine Tumors) trial...

2011-04-12 08:22:00

BERLIN, April 12, 2011 /PRNewswire/ -- OctreoPharm Sciences GmbH, a specialist for contrast media in Nuclear Medicine, was able to successfully close a financing round for the clinical development of its cancer diagnostic SOMscan(R).

2011-04-11 12:16:00

SILVER SPRING, Md., April 11, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights for this week from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists.


Word of the Day
overword
  • To say in too many words; to express verbosely.
  • To express in too many words: sometimes used reflexively.
  • The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.
The word 'overword' comes from over- +‎ word.